Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Roche announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.

  • Researchers found that a new combination therapy was highly effective at treating patients with melanoma, which is known as the most serious type of skin cancer. The findings were published online in the Journal of the American Academy of Dermatology.

  • Nearly 30 per cent of all liver for transplantation is rejected because the donors have 'fatty livers', a disease which is likely to increase in future, the government said. Minister of State for Health Shripad Naik said that the prevalence of non-alcoholic fatty liver disease (NAFLD) is considered to be a known cause of rejection for liver transplantation because of accumulation of fat in the liver.

  • A survey has found that over 11 per cent people in Delhi are suffering from Asthma and Rhinits, the government today said while acknowledging that air pollution is an "aggravating" factor for respiratory and cardiovascular diseases. "As per a survey conducted by Vallabbhai Patel Chest Institute Delhi in 2006, which covered 5,900 adults belonging to urban, rural and slum population in Delhi, 11.69 per cent were found to be suffering from Rhinits and 11.03 per cent from Asthma," Health Minister J P Nadda informed the Lok °Sabha.

Subscribe to Pharma News